Novartis' Fabhalta (iptacopan) receives FDA accelerated approval as a first-in-class complement inhibitor for IgA nephropathy, reducing proteinuria in adults at risk of rapid disease progression.

Novartis NVS announced that the FDA has approved Fabhalta (iptacopan) for a third indication. The regulatory body approved the drug for the treatment of adults with C3 glomerulopathy (C3G) to ...

Bayer. In the past 30 days, Bayer’s earnings per share (EPS) estimate for 2025 has increased to $1.19 from $1.14. During the same timeframe, the figure for 2026 has increased to $1.28 from $1.23.

With the expanded approval, Novartis' drug entered the IgA nephropathy ... US FDA approves Novartis' kidney disease drug. Sriparna Roy. August 7, 2024 at 11:23 AM. Copied; By Sriparna Roy ...

Novartis’s iptacopan met the first of two main goals in its pivotal study in immunoglobulin A nephropathy, and the pharma giant plans to seek accelerated FDA approval next year. The drug could ...

Novartis' Fabhalta receives FDA approval for C3 glomerulopathy, expanding its kidney disease portfolio as global regulatory reviews continue.

C3G is a progressive and ultra-rare kidney disease that is typically diagnosed in young adults and often progresses to kidney failure. Per NVS, this is the first and only treatment approved for ...

On Thursday, the FDA granted accelerated approval to Novartis AG’s (NYSE:NVS) Fabhalta (iptacopan), a first-in-class complement inhibitor for the reduction of proteinuria in adults with primary ...